Flamel Technologies (FLML) Announces Completion Of A Commercial Supply Agreement With GlaxoSmithKline (GSK) For Drug In Phase III Trials 
10/19/2005 5:12:30 PM

LYON, France--(BUSINESS WIRE)--Dec. 21, 2004--Flamel Technologies S.A. ("Flamel") (Nasdaq:FLML) announced today that Flamel and Glaxo-Smith Kline ("GSK") have signed an agreement whereby Flamel will supply GSK with commercial supplies of Flamel's Micropump(R) formulation of a major, currently-marketed, GSK drug. The provisions of the agreement include payments such that Flamel will not have cash outlays in connection with equipment to be used.